Ribavirin and interferon alfa-2b in chronic hepatitis C: Assessment of possible pharmacokinetic and pharmacodynamic interactions

British Journal of Clinical Pharmacology

Volumn 46, Issue 6, 1998, Pages 563-570

  Khakoo, Salim ^a   Glue, Paul ^b   Grellier, Leonie ^c   Wells, Beverley ^d   Bell, Allan ^e   Dash, Clive ^e   Murray Lyon, Lain ^a   Lypnyj, David ^b   Flannery, Brian ^c   Walters, Karen ^d   Dusheiko, Geoffrey M ^e  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b LAB Clinical Trials Unil   (United States)

^c Clmrchill Clementine Hospital   (United States)

^d CHARING CROSS HOSPITAL   (United Kingdom)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

2'5' oligoadenylate synthetase; Drug interaction; HCV RNA; Hepatitis C; Interferon alfa 2b; Neopterin; Pharmacodynamics; Pharmacokinetics; Ribavirin

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; HEMOGLOBIN; NEOPTERIN; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HUMAN; INFLUENZA; INSOMNIA; LEUKOCYTE COUNT; MALE; MYALGIA; NAUSEA; NEUTROPHIL; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DRUG INTERACTIONS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN;

EID: 7844238614     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00836.x     Document Type: Article

References (24)

1. Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus intcrferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-817.
2. Brouwer JT, Nevens F, Michielsen P, et al. What options are left when hepatitis C does not respond to interferon? Placebocontrolled Benelux multicentre retreatment trial on ribavirin monotherapy versus combination with interferon (abstract WP2/08).y Hepatol 1994; 21 Suppl 1: S17.
3. Chemello L, Cavaletto L, Bcrnardinell E, et al. Response to ribavirin, to interferon and to a combination of both in patients with chronic hepatitis C and its relation to HCV genotypes (abstract GS 5/29). J Hepatol 1994; 21 Suppl 1: S12.
4. Reichard O, Norkrans G, Fryden A, et al. Randomized double-blind placebo-controlled study of Interferon oc-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-87.
5. Israel BC, Blouin RA, Mclntyre W, Shedlofsky SI. Effects of interfcron-a on hepatic drug metabolism in cancer patients. B J Clin Pharmacol 1993; 36: 229-235.
6. Garrattini S. Perspectives in the field of drug metabolism. Dn/j Metab Rev 1994; 26: 537-573.
7. Laskin ÖL, Longstreth JA, Hart ÇA, et al. Ribavirin disposition in high risk patients for acquired immunodeficiency syndrome. Clin Pliannacol Tlier 1987; 41: 546-555.
8. Lertora JJL, Rege AB, Lacour JT, et al. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Phannacol Tlicr 1991; 50: 442-449.
9. Gibaldi M, Pcrrier D. Pharmacokinetics, 2nd ed. New York, Marcel Dekker, 1982, 409-417.
10. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. Aim Int Med 1995; 123: 897-903.
11. Catlin DH, Smith RA, Samuels AI. 14C-Ribavirin distribution and pharmacokinetic studies in rats, baboons and man. In Ribavirin: A broad spectrum antiviral agent, eds Smith RA, Kirkpatrick W, New York, Academic Press, 1980, pp 83-98.
12. Ferrara EA, Oishi JS, Wannemacher RW Jr, et al. Plasma dissapearance, urine excretion and tissue distribution of ribavirin in rats and rhesus monkeys. Antimicrob Agents Chemother 1981; 19: 1042-1049.
13. Steinijans VW, Hartmann M, Huber R, et al. Lack of pharmacokinetic interaction as a bioequivalence problem, hit J Clin Phannacol Toxicol 1991; 29: 323-328.
14. Piscitelli SC, Amantea MA, Vogel S, et al. Effects of cytokines on antiviral pharmacokinetics: an alternative approach to assessment of drug interactions using bioequivalence guidelines. Antimicrob Agents Chemother 1996; 40: 161-165.
15. Paroni R, Del Puppo M, Borghi C, et al. Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers. IntJ Clin Phannacol Tlier Toxicol 1989; 27: 302-307.
16. Jarvis SM, Thorn JA, Glue P. Ribavirin uptake by human erythrocytes is mediated by es nucleoside transporters. Br J Phannacol 1998; (in press).
17. Griffith, DA, Jarvis, SM. Nucleoside and nucleobase transport systems of mammalian cells. Diochiin Biopliys Ada, 1996; 1286: 153-181.
18. Griffiths, M, Beaumont, N, Yao, SYM, et al. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapcutic drugs. Nature Medicine, 1997; 3, 89-93.
19. Nakajima S, Kuroki T, Shintani M, et al. Changes in interferon receptors on peripheral blood lymphocytes in patients with chronic hepatitis B being treated with interferon. Hcpatology 1990; 12: 1261-1265.
20. Pestka S, Langer JA, Zoon KC, Samuel CE. Interférons and their actions. Ann Rev Biochcin 1987; 56: 727-777.
21. Fuchs D, Weiss G, Reibnegger G, Wächter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases. Crit Rev Clin Lab Sei 1992; 29: 307-341.
22. Witt PL, Storer BE, Bryan GT, et al. Pharmacodynamics of biological response in vivo after single and multiple doses of Interferon-β.J Imiminother 1993; 13: 191-200.
23. Musolino C, Grosso P, Alonci A, et al. Serum levels of 2'5' oligoadenylate synthetase during interferon therapy in patients with B-cell chronic lymphocytic leukemia. Am J Hematol 1993; 43: 1-4.
24. Glue P, Cutler D, Sabo R, et al. Pharmacodynamic effects of interferon alfa-2b in healthy volunteers. Clin Phannacol Tlier 1996; 59: 205 (abstract).